FFAR1 Agonists with Oxazolyl Core for Metabolic Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions targeting free fatty acid receptors (FFARs), particularly FFAR1, face challenges such as toxicity issues and lack of selectivity, which hinder their development as effective treatments for metabolic disorders.
Innovation Solution
Development of a pharmaceutical composition comprising compounds of general formula (I), specifically R1-S-CH2-OXA-R2, where OXA is a 1,3-oxazolyl, 1,2,4-oxadiazolyl, or 1,3,4-oxadiazolyl core moiety, designed to act as agonists for FFAR1 with enhanced selectivity and reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If known FFAR1 agonists (e.g., TAK-875, LY2881835, AMG 837) are used to treat metabolic disorders, then insulin secretion is stimulated and blood glucose control is improved, but liver toxicity occurs and clinical development is terminated
Solution Approach 1:
The patent modifies the chemical structure of known FFAR1 agonists by changing molecular parameters (introducing specific substituent groups R1 and R2 at defined positions) to create analogs with improved safety profiles. This structural parameter optimization maintains pharmacological activity while reducing hepatotoxicity, allowing clinical development to proceed
2Adaptability or versatility
If FFAR1 agonists with broad receptor activity are used, then multiple physiological effects are achieved, but selectivity over other FFAR family receptors is lost leading to off-target effects
Solution Approach 1:
The patent introduces specific local structural features (defined substituent groups at R1 and R2 positions) that confer selective binding properties to the FFAR1 receptor while maintaining activity. These localized molecular modifications enable the compound to distinguish FFAR1 from other FFAR family members, reducing off-target effects while preserving therapeutic benefits
3Productivity
If potent FFAR1 agonists are developed to amplify insulin secretion, then diabetes treatment efficacy is improved, but risk of hypoglycemia increases
Solution Approach 1:
The patent designs agonists with optimized potency levels that provide sufficient insulin secretion amplification for effective diabetes treatment without excessive activation that would cause hypoglycemia. The molecular structure is tuned to achieve partial agonism or controlled full agonism, balancing therapeutic efficacy with safety margins
Data Source
Figure 1
Figure 1
Figure 1
AI summary
The present invention relates to novel free fatty acid receptor (FFAR) agonists (I), in particular agonists of FFAR1, and to the use of said FFAR agonists as medicaments, in particular for treatment and/or prevention of conditions or diseases amenable to enhanced activity of FFAR1 such as of conditions or diseases involving impaired control of glucose blood levels, metabolic syndrome, obesity, dyslipidemia, kidney diseases, fibrotic and sclerotic diseases as well as hepatic and biliary diseases. R1-S-CH2-OXA-R2 (I).